Cipla receives FDA OK for generic Firazyr

Patients with acute attacks of hereditary angioedema who are 18 years of age and older will soon have a new generic treatment option.

The Food and Drug Administration has approved Cipla’s Icatibant injectable in a dosage strength of 30mg/3mL to treat this condition.

The product is the generic of Shire's Firazyr.

Firazyr and its generic equivalents had a market value of approximately $270 million for the 12 month period ending May 2020, according to IQVIA.